Transarterial chemoembolization is a procedure to treat liver cancer. It is a therapy for patients with intermediate-stage hepatocellular carcinoma (HCC), and working is based on blocking the blood supply to the tumor. Chemotherapy is given right into the tumor once the supply is blocked. Conventional transarterial chemoembolization is popular as a standard treatment for HCC. Transarterial chemoembolization also utilizes microspheres as drug carriers, which aids to decrease the concentration of chemotherapeutics in the systemic circulation of patients.
COVID-19 Impact analysis
COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the transarterial chemoembolization market.
Top Impacting Factors
- Increase in cases of hepatocellular carcinoma (HCC), constant growth of drug consumption, and the development of cardiovascular diseases, and rise in demand for advanced cancer treatment and procedures are factors that drive the growth of the transarterial chemoembolization market.
- In addition, increase in healthcare expenditure; availability of skilled professionals, and rise in R&D activities to develop and launch novel therapies in the market; are some factors, which boost the market growth for transarterial chemoembolization.
- However, higher cost of treatment and complications associated with embolization may hinder the market growth.
- Contrarily, favorable reimbursement policies and support from the government for regulatory approval present new pathways in the industry.
Transarterial Chemoembolization Market Trends
New product launches to flourish the market
AstraZeneca is currently conducting three phases 3 studies to evaluate durvalumab. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1. One of the current studies includes EMERALD-1 (transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab). The safety and clinical activity of durvalumab monotherapy were reported in June of 2017.
Key Benefits of the Report
- This study presents the analytical depiction of the transarterial chemoembolization industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the transarterial chemoembolization market share.
- The current market is quantitatively analyzed to highlight the transarterial chemoembolization market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed transarterial chemoembolization market analysis based on competitive intensity and how the competition will take shape in coming years
Questions answered in the transarterial chemoembolization Report
- Which are the leading players active in the transarterial chemoembolization market?
- What are the current trends that will influence the transarterial chemoembolization market in the next few years?
- What are the driving factors, restraints, and opportunities of the transarterial chemoembolization market?
- What future projections would help in taking further strategic steps?
- What is "Transarterial chemoembolization"?
- What is "Transarterial chemoembolization" Market prediction in the future?
- Who are the leading global players in the "Transarterial chemoembolization" Market?
- What are the current trends and predicted trends?
- What are the key benefits of the "Transarterial chemoembolization" Market report?
Transarterial Chemoembolization Market Report Highlights
| Aspects | Details |
 By Product Type |
|
 By Procedure Type |
|
 By Indication |
|
 By End User |
|
 By Region |
|
 Key Market Players | Siemens Healthcare GmbH, Hikma Pharmaceuticals PLC, Spectrum Pharmaceuticals, Inc., Cook, Nippon Kayaku Co. Ltd., Bellicum Pharmaceuticals Inc., Questex LLC., Boston Scientific Corporation, CELGENE CORPORATION, Pfizer Inc., Bayer AG, Novartis AG, F. Hoffmann-La Roche Ltd, Merck & Co., Inc. |
Loading Table Of Content...
